The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

被引：0
|
作者：
Ashok Jha
Alex Upton
William C. N. Dunlop
Ron Akehurst
机构：
[1] Mundipharma International Ltd.,School of Health and Related Research (ScHARR)
[2] Abacus International,undefined
[3] University of Sheffield,undefined
[4] BresMed Health Solutions Limited,undefined
[5] Northchurch Business Centre,undefined
来源：
Advances in Therapy | 2015年 / 32卷
关键词：
Ankylosing spondylitis; Biosimilar; Crohn’s disease; Infliximab; Psoriasis; Psoriatic arthritis; Remicade; Remsima; Rheumatoid arthritis; Ulcerative colitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：742 / 756
页数：14
相关论文
共 30 条
  • [21] Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
    Hyun Kyeong Yoo
    Han Geul Byun
    Flavio Caprioli
    Mathurin Fumery
    Laurent Peyrin-Biroulet
    Subramanian Sreedhar
    James Potter
    Minyoung Jang
    BMC Health Services Research, 22
  • [22] Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
    Yoo, Hyun Kyeong
    Byun, Han Geul
    Caprioli, Flavio
    Fumery, Mathurin
    Peyrin-Biroulet, Laurent
    Sreedhar, Subramanian
    Potter, James
    Jang, Minyoung
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [23] Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
    Stajszczyk, Marcin
    Obarska, Izabela
    Jeka, Slawomir
    Batko, Bogdan
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (09) : 1171 - 1180
  • [24] Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases
    Jin, Ran
    Kruppert, Silvia
    Scholz, Florian
    Bardoulat, Isabelle
    Karzazi, Khalil
    Morand, Francois
    Kricorian, Greg
    Collier, David
    Kay, Jonathan
    RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 523 - 537
  • [25] Real world effectiveness and satisfaction with secukinumab in the treatment of patients with psoriatic arthritis: a population survey in five European countries
    Conaghan, Philip G.
    Keininger, Dorothy L.
    Holdsworth, Elizabeth A.
    Booth, Nicola
    Modi, Niraj N.
    Tian, Haijun
    Kiltz, Uta
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (10) : 1845 - 1853
  • [26] High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases
    Sasson, Alexa N.
    Ananthakrishnan, Ashwin N.
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (07) : 3124 - 3128
  • [27] High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases
    Alexa N. Sasson
    Ashwin N. Ananthakrishnan
    Digestive Diseases and Sciences, 2022, 67 : 3124 - 3128
  • [28] Treatment patterns and outcomes of patients with complex Crohn's perianal fistula in five European countries: the PREFACE study
    Ferrante, M.
    Siproudhis, L.
    Poggioli, G.
    Reinshagen, M.
    Milicevic, S.
    Roset, M.
    Bentennakhil, N.
    Fernandez-Nistal, A.
    Panes, J.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2024, 87 (03) : 494 - 504
  • [29] Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data
    Yang, Jingyan
    Liu, Rongzhe
    Granghaud, Anna
    Zaidi, Omer
    Stephens, Jennifer
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 665 - 674
  • [30] Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study
    Sun, Diana
    Andayani, Tri Murti
    Altyar, Ahmed
    MacDonald, Karen
    Abraham, Ivo
    CLINICAL THERAPEUTICS, 2015, 37 (04) : 842 - 857
123